Hennion & Walsh Asset Management Inc. Sells 6,061 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Hennion & Walsh Asset Management Inc. trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 8.8% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 62,911 shares of the biotechnology company’s stock after selling 6,061 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Exelixis were worth $1,633,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the third quarter worth approximately $30,000. Park Place Capital Corp bought a new stake in Exelixis in the 2nd quarter worth approximately $45,000. GAMMA Investing LLC grew its position in Exelixis by 107.9% in the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,041 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,746 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Exelixis in the 3rd quarter worth $74,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on EXEL. UBS Group initiated coverage on Exelixis in a research report on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. Truist Financial restated a “buy” rating and set a $33.00 target price (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. Bank of America increased their price target on shares of Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Finally, Morgan Stanley boosted their price objective on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, October 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.57.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the sale, the executive vice president now directly owns 520,990 shares of the company’s stock, valued at approximately $13,024,750. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares in the company, valued at $19,622,479.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Dana Aftab sold 95,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares in the company, valued at approximately $13,024,750. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 327,858 shares of company stock valued at $8,640,129 in the last 90 days. Insiders own 2.85% of the company’s stock.

Exelixis Trading Down 0.9 %

Shares of EXEL opened at $27.87 on Friday. Exelixis, Inc. has a 12-month low of $19.20 and a 12-month high of $29.75. The company has a market capitalization of $7.95 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54. The business’s 50 day moving average is $26.61 and its 200 day moving average is $24.00.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The firm had revenue of $637.18 million for the quarter, compared to the consensus estimate of $468.21 million. Equities research analysts predict that Exelixis, Inc. will post 1.58 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.